|
|
|
| Thrombolytic effect of Alteplase combined with Heparin in treatment of acute ST segment elevation myocardial infarction |
| WANG Hui MA Ganfang |
| Department of Emergency, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China |
|
|
|
Abstract Objective To discuss the therapeutic effect of Heparin combined with Aheplase as the intravenous thrombolytic therapy treating acute STEMI. Methods From July 2017 to April 2018, in Department of Emergency, Beijing Ditan Hospital, Capital Medical University, 137 patients with acute STEMI were selected, they were divided into the control group (67 cases) and the observation group (70 cases) according to the random number table method. The control group was treated with urokinase as the intravenous thrombolysis, and the observation group was treated with Heparin and Aheplase. The changes of electrocardiogram, the changes of myocardial enzymes, the degree of remission of the symptoms and the arrhythmia of reperfusion after thrombolytic treatment were observed, the preliminary judgement whether the blood vessels were reconnected after thrombolytic, and further remedial PCI was performed to determine the recanalization condition indeed, the monitor the incidence of cardiogenic shock, malignant arrhythmia, heart failure and death were continuously given during the period of hospitalization. Results The total efficacy in the observation group was higher than the control group, the difference was statistically significant (P < 0.01); the incidence of cardiovascular events in the observation group was lower than in the control group, the difference was statistically significant (P < 0.01). Conclusion Heparin combined with alteplase as the intravenous thrombolytic therapy is superior to urokinase, and can also reduce the incidence of cardiovascular events in STEMI patients.
|
|
|
|
|
|
[1] Burger KN，Beulens JW，Boer JM，et al. Dietary glycemic load and glycemic index and risk of coronary heart disease and stroke in Dutch men and women：The EPIC-MORGEN study [J]. PLOS One，2011，6（10）：255.
[2] 陈伟伟，高润霖，刘力生，等.《中国心血管病报告2016》概要[J].中国循环杂志，2017，32（6）：521-530.
[3] 国家卫生和计划生育委员会.中国卫生和计划生育统计年鉴2016[M].北京：中国协和医科大学出版社，2017.
[4] 颜红兵，向定成，刘红梅，等.ST段抬高型急性心肌梗死院前溶栓治疗中国专家共识[J].中国介入心脏病学杂志，2018，26（4）：181-190.
[5] 中华医学会心血管病学分会.急性心肌梗死诊断和治疗指南[J].中华心血管病杂志，2001，29（12）：710-725.
[6] 沈卫峰，沈迎，张奇，等.2015年《急性ST段抬高型心肌梗死诊断和治疗指南》解读[J].中国循环杂志，2015，30（s2）：7-8.
[7] 中华医学会心血管病学分会.急性ST段抬高型心肌梗死诊断和治疗指南[J].中华心血管病杂志，2015，43（5）：380-393.
[8] Bruno CA，Meyers PM. Endovascular procedures versus intravenous thrombolysis in stroke patients with tandem occlusion of the anterior circulation [J]. J Vasc Interv Radiol，2014，25（8）：1165-1170.
[9] Souiki T，Tekni Z，Laachach H，et al. Catastrophic hemorrhage of adrenal pheochromocytoma following thrombolysis for acute myocardial infarction：case report and literature review [J]. World J Emerg Surg，2014，9（1）：50.
[10] 童随阳，夏豪，王欣，等.阿替普酶与尿激酶治疗急性心肌梗死的有效性与安全性[J].中国医药导报，2014，11（33）：75-79.
[11] Sugioka K，Kodama A，Yoshida K，et al. The roles of urokinase plasminogen in leukocyte infiltration and inflammatory responses in mice corneas treated with lipopolysaccharide （LPS） [J]. Invest Ophthalmol Vis Sci，2014，55（8）：5338-5350.
[12] Triantafyllou K，Metaxopoulos P，Babalis D. Primary percutaneous coronary intervention of an unprotected left main using mini-crush drug-eluting stents facilitated by intracoronary reteplase [J]. Catheter Cardiovasc Interv，2011，77（4）：515-521.
[13] Aasa M，Dellborg M，Herlitz J，et al. Risk reduction for cardiac events after primary coronary intervention compared with thrombolysis for acute ST-elevation myocardial infarction （five-year results of the Swedish early decision reperfusion strategy [SWEDES] trial） [J]. Am J Cardiol，2010，106（12）：1685-1691.
[14] 胡彬.阿替普酶与尿激酶溶栓治疗急性心肌梗死的疗效对比分析[J].实用药物与临床，2013，16（10）：960-962.
[15] Gao L，Zhang C，Li L，et al. Construction, expression and refolding of a bifunctional fusion protein consisting of C-terminal 12-residue of hirudin-PA and reteplase [J]. Protein J，2012，31（4）：328-336.
[16] 李欢.阿替普酶与尿激酶溶栓治疗急性ST段抬高型心肌梗死临床疗效的对比研究[J].实用心脑肺血管病杂志，2015，23（3）：147-148.
[17] 金洪珍，周淑文，许丁.尿激酶与阿替普酶在急性心肌梗死溶栓治疗中的疗效比较[J].中国循证心血管医学杂志，2013，5（3）：304.
[18] Aflakiyan S，Sadeghi HM，Shokrgozar M，et al. Expression of the recombinant plasminogen activator（reteplase）by a non-lytic insect cell expression system [J]. Res Pharm Sci，2013，8（1）：9-15.
[19] 杜立峰.阿替普酶与尿激酶分别联合依诺肝素钠治疗急性ST段抬高型心肌梗死的临床疗效、安全性和经济性分析[J].中西医结合心血管病电子杂志，2017，5（6）：22-23.
[20] Pheerawong P，Plienthaisong B. Outcome of recombinant tissue plasminogen activator in ST-segment elevation myocardial infarction in Buriram Hospital [J]. J Med Assoc Thai，2014，97（8）：804-811. |
|
|
|
